TheEdgeResearch
Home / Stocks / PTIX

Protagenic Therapeutics, Inc. (PTIX)

OTC Healthcare Biotechnology
$0.77 ▼ -10.00%
Market Cap
$1.4M
Sector
Healthcare
Industry
Biotechnology
Beta
1.07
52-Wk Range
0.128-4.42
CEO
Garo H. Armen
Country
US
Currency
USD

Protagenic Therapeutics, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in New York, NY, US. The stock last traded at $0.77, down 10.00% on the session, giving a market capitalisation of $1.4M. On trailing twelve-month figures it carries a trailing P/E of 0.26, a net margin of 0.0%. Its beta of 1.07 implies it has historically moved more than the broad market.

Valuation & profitability (TTM)
P/E
0.26
Price / Sales
0.00
Price / Book
0.81
EV / EBITDA
-0.21
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
Return on equity
—
Debt / equity
0.00
Current ratio
0.66
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
Other OTC
Employees
2
IPO date
2021-04-27
Headquarters
New York, NY, US
About Protagenic Therapeutics, Inc.

Protagenic Therapeutics, Inc. operates as a pharmaceutical company specializing in the development of medicines manufactured from cannabinoid and cannabinoid-like molecules. Protagenic Therapeutics, Inc. was founded in 2004 and is based in Santa Barbara, California.

Comparable companies

Protagenic Therapeutics, Inc. is most often compared with the following Healthcare names:

ARTLCARMGTBPINDPLIPOPBMREVBSLRXSLXNSPRC
More research on PTIX
PTIX technical analysis PTIX TheEdge Score Compare against peers
Open full interactive analysis & DCF →